Search
olokizumab
Indications:
- long-term managemtne of rheumatoid arthritis in combination with methotrexate
Dosage:
- subcutaneous once every 2 weeks or once every 4 weeks
Adverse effects:
- neutropenia
- elevated serum transaminases
- dyslipidemia
Mechanism of action:
- humanized monoclonal antibody targeting interleukin-6
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
References
- Feist E, Fleischmann RM, Fatenejad S et al
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.
Ann Rheum Dis. 2024 Jul 2:ard-2023-225473.
PMID: 38955475 Free article.
- Smolen JS, Feist E, Fatenejad S
Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.
N Engl J Med. 2022 Aug 25;387(8):715-726.
PMID: 36001712 Clinical Trial.
https://www.nejm.org/doi/10.1056/NEJMoa2201302